Efficacy and Safety of ALSS Treatment for ICIs-LF in Patients With HCC

Prior treatment

• Patients received artificial liver support system treatment in one week before inclusion;

Other illness

• Other active liver diseases;
• Other malignancy;
• Human immunodeficiency virus infection or congenital immune deficiency diseases;
• Severe diabetes, autoimmune diseases; unstable infarction due to cardio-cerebrovascular events; other important organ dysfunctions or transplantation;
• Active bleeding, disseminated intravascular coagulation, thrombosis, or thrombotic disease;

Other

• Pregnancy or lactation;
• Patients can not follow-up;
• Investigator considering inappropriate

• Age from 18 to 65 years old;
• Clinical diagnosis of chronic hepatitis b virus infection (positive hepatitis b surface antigen or positive hepatitis b virus DNA \> 0.5 year);
• Clinical diagnosis of hepatocellular carcinoma and receive immune checkpoint inhibitors treatment. The last treatment of immune checkpoint inhibitors is less than three months from inclusion;
• The level of hepatitis b virus DNA \< 2000 IU/mL；
• Serum aspartate aminotransferase/alanine aminotransferase \> 20 times upper limit of normal；serum total bilirubin\>10 times upper limit of normal；
• Prothrombin time international ratio \> 1.5;
• Platelets \> 50\*10 E9/L;
• Without intrahepatic bile duct dilation due to tumor progression.